SYNACT PHARMA
SynAct Pharma AB develops drugs for acute deterioration in inflammatory diseases. The company's drug candidate AP1189 is intended for the treatment of arthritis including psoriatic arthritis - a form of acute joint disorder that affects approximately 30 percent of patients suffering from psoriasis. Preclinical studies show that AP1189 has a unique ability to both reduce inflammation and accelerate bleeding, which is expected to reduce joint damage that may occur after acute inflammation of the ... joints of the joints. AP1189 has the potential to be given in tablet form once a day. Results from a clinical phase I study are expected to be available during Q2 2018. The company intends to prepare for a first patient study in parallel with the completion of the phase I study. Assuming that AP1189 has proven safe and tolerable also in multiple dosing, the aim is to submit a clinical trial application (CTA) in patients with active arthritis (joint inflammation). After proof of concept has been shown in patients, the company intends to sign commercial agreements with one or more major pharmaceutical companies.
SYNACT PHARMA
Social Links:
Industry:
Biotechnology Health Care
Founded:
2012-01-01
Address:
Lund, Skane Lan, Sweden
Country:
Sweden
Website Url:
http://www.synactpharma.com
Total Employee:
1+
Status:
Active
Contact:
+45 28 44 75 67
Email Addresses:
[email protected]
Total Funding:
71.43 K EUR
Technology used in webpage:
Google Tag Manager Content Delivery Network WordPress US Privacy User Signal Mechanism Cloudflare CDN Cloudflare Cloudflare JS CDN JS COVID-19 UNPKG
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Edison Pharmaceuticals
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Pandion Therapeutics
Pandion Therapeutics develops innovative modular proteins, antibodies, and bispecifics for autoimmune and inflammatory diseases.
SFA Therapeutics
SFA Therapeutics is a developer of drugs to treat chronic inflammatory diseases.
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-12-12 | TXP Pharma | TXP Pharma acquired by SynAct Pharma | 136 M USD |
Investors List
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - SynAct Pharma
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-07 | SynAct Pharma appoints Patrik Renblad as CFO |
| 2021-01-26 | SynAct Pharma names Thomas Boesen as Chief Operating Officer |
Official Site Inspections
http://www.synactpharma.com Semrush global rank: 1.9 M Semrush visits lastest month: 11.98 K
- Host name: 104.18.12.243
- IP address: 104.18.12.243
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "SynAct Pharma"
Organisation – SynAct Pharma
SynAct Pharma AB is a Swedish public company (Org. No: 559058-4826) listed on Nasdaq Stockholm, with its headquarters in Lund, Sweden. Research and...See details»
ANNUAL REPORT - SynAct Pharma
[email protected] CONTENT CEO Letter.3 Business, vision and mission.4 History.5 Technology, market and intellectual property.6 The share, share capital and ownership.14 The …See details»
SynAct Pharma
Dec 17, 2024 Our lead drug candidate resomelagon (AP1189) is a once-daily oral selective melanocortin agonist that selectively stimulates melanocortin receptors to help the body resolve …See details»
SynAct Pharma - Crunchbase Company Profile
SynAct Pharma AB develops drugs for acute deterioration in inflammatory diseases. The company's drug candidate AP1189 is intended for the treatment of arthritis including psoriatic arthritis - a form of acute joint disorder that …See details»
SynAct Pharma - Company Profile & Staff Directory - ContactOut
SynAct Pharma is a biotech company aiming at resolving inflammation by leveraging melanocortin biology. Our lead asset AP1189 is in phase 2 development for the treatment of rheumatoid …See details»
SynAct Pharma Overview | SignalHire Company Profile
Organization Website: synactpharma.com : SynAct Pharma industries Biotech: Headquarters Location: Medicon Village AB, Sheelevägen 2, Lund, SE-223 81 SE Medicon Village AB, …See details»
SynAct Pharma AB Company Description - Stock Analysis
Dec 23, 2024 Company profile for SynAct Pharma AB (STO: SYNACT) with a description, list of executives, contact details and other key facts.See details»
SynAct Pharma - Overview, News & Similar companies - ZoomInfo
Jan 27, 2024 Who is SynAct Pharma. SynAct Pharma AB conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of …See details»
SynAct Pharma - LinkedIn
SynAct Pharma is a biotech company aiming at resolving inflammation by leveraging melanocortin biology. Our lead asset AP1189 is in phase 2 development for the treatment of rheumatoid …See details»
SynAct Pharma AB - Drug pipelines, Patents, Clinical trials - Synapse
Explore SynAct Pharma AB with its drug pipeline, therapeutic area, technology platform, 9 clinical trials, 17 news, and 2 literature, Disease Domain:Immune System ...See details»
SynAct Pharma - Company Profile - Tracxn
Oct 11, 2024 What are the most recent funding rounds of SynAct Pharma? Its latest funding round was a Grant (prize money) round on Sep 30, 2018 for $58K. 1 investor participated in its …See details»
The Company in Brief – SynAct Pharma
SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune …See details»
Change in number of shares and votes in SynAct Pharma AB
Dec 30, 2024 The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and anti-inflammatory activity in autoimmune and …See details»
SynAct Pharma announces its 2024 strategic plan and milestones
Feb 2, 2024 Mail: [email protected]. Mail: [email protected]. About SynAct Pharma AB. SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical …See details»
Investors – SynAct Pharma
The interim report for Q3 2024 was published on October 30, 2024, at 07.30 CEST.See details»
SynAct Pharma announces its 2024 strategic plan and milestones
Feb 2, 2024 SynAct Pharma AB (Nasdaq Stockholm: SYNACT), a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the …See details»
SynAct Pharma publishes Q3 2024 interim results - TradingView
Oct 30, 2024 E-mail: [email protected] Björn Westberg CFO, SynAct Pharma AB Phone: +46 703 33 91 23. E-mail: [email protected]. About SynAct Pharma AB. SynAct …See details»
History – SynAct Pharma
The company carries out a rights issue of approximately SEK 22.4 million for the extended development program for AP1189. The company announces that the tablet formulation of …See details»
SynAct Pharma AB publishes Annual Report 2021
Apr 29, 2022 SynAct Pharma AB (“SynAct”) today announces that the Annual Report for 2021 is now available as a pdf on the group’s web page, www.synactpharma.com. A pdf version is …See details»